SV2A
ENSG00000159164
Target class
Transporter
Chromosome
1
Approved drugs
2
Clinical candidates (approved and in development)
4
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- SV2A
- Gene name
- Synaptic vesicle glycoprotein 2A
- Gene symbol
- SV2A
- Protein name
- Synaptic vesicle glycoprotein 2A
- SV2
- KIAA0736
- SLC22B1
- Gene biotype
- Protein coding
- Gene family
- Solute carrier family 22
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 49
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 215.53
- Tissue specificity (Gini)
- 0.719
- Tissue specificity (tau)
- 0.882
- KEGG gene identifiers
- hsa:9900
- Protein interaction confidence
- 0.813
- Protein interaction partners
- 13
- R-HSA-5250955
- R-HSA-5250968
- R-HSA-5250981
- R-HSA-5250992
- End position
- 149918572
- Start position
- 149903318
- Chromosome
- 1
- Strand
- Reverse
- Presynapse . Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane
- Multi-pass membrane protein . Note=Enriched in chromaffin granules, not present in adrenal microsomes. Associated with both insulin granules and synaptic-like microvesicles in insulin-secreting cells of the pancreas (By similarity). Colocalizes with ATP2B1 at photoreceptor synaptic terminals. .
- Cytosol
- Tissue specificity (tau)
- 0.882091
- Expression inequality (Gini)
- 0.718508
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 215.53
- Brain - Cerebellum
- 208.81
- Brain - Frontal Cortex (BA9)
- 175.34
- Brain - Cortex
- 124.1
- Brain - Anterior cingulate cortex (BA24)
- 94.96
Expression in transcripts per million
- Brain - Cerebellar Hemisphere215.53
- Brain - Cerebellum208.81
- Brain - Frontal Cortex (BA9)175.34
- Brain - Cortex124.1
- Brain - Anterior cingulate cortex (BA24)94.96
- Brain - Hypothalamus91.09
- Brain - Nucleus accumbens (basal ganglia)74.76
- Brain - Caudate (basal ganglia)61.78
- Brain - Hippocampus51.75
- Brain - Amygdala51.61
- Brain - Putamen (basal ganglia)48.46
- Brain - Substantia nigra44.71
- Pituitary44.35
- Artery - Aorta33.5
- Brain - Spinal cord (cervical c-1)30
- Uterus19
- Artery - Tibial15.51
- Cervix - Endocervix15.14
- Cells - Cultured fibroblasts14.4
- Artery - Coronary13
- Cervix - Ectocervix10.52
- Fallopian Tube10.35
- Esophagus - Gastroesophageal Junction9.8
- Colon - Sigmoid8.21
- Prostate8.08
And 29 more, listed on the interactive page.
- GO:0005783
- GO:0005886
- GO:0008021
- GO:0030672
Related records
Trials (344)
- 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
- A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)
- A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
- A Bioequivalence Study of Levetiracetam Versus Keppra
- A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males
- A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants
- A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
- A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches
- A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
- A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
- A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)
- A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures
- A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
- A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
- A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
- A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures
- A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
- A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
- A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy
Drugs (4)
- Brivaracetam Synaptic vesicle glycoprotein 2A modulator
- Levetiracetam Synaptic vesicle glycoprotein 2A modulator
- Padsevonil Synaptic vesicle protein modulator
- Seletracetam Synaptic vesicle glycoprotein 2A modulator